文献速递生殖医学

根据女性年龄确定体外受精治疗周期中获得至少一个整倍体囊胚所需成熟卵母细胞的最小数量

Minimum number of mature oocytes needed to obtain at least one euploid blastocyst according to female age in in vitro fertilization treatment cycles.
PubMed 文献 · Fertil Steril · 2024-06-05

该回顾性分析纳入西班牙IVIRMA Valencia在2017年1月至2022年3月间进行的2660个IVF-PGT-A治疗周期,患者组2462个(年龄≥35岁自卵),供卵组198个(≤34岁)。结果显示获得至少一个整倍体囊胚所需的MII卵母细胞平均数随年龄增加而增加,未获得整倍体囊胚的周期数也随年龄增加。基于80%患者组样本建立的预测模型在剩余20%样本中验证,估计至少获得一个整倍体囊胚的准确率为72.0%。

要点

  • 获得至少一个整倍体囊胚所需的MII卵母细胞平均数随女性年龄增加而增加。
  • 未获得至少一个整倍体囊胚的治疗周期数也随女性年龄增加而增加。
  • 基于患者组80%样本建立的预测模型在20%验证集中的准确率为72.0%。

核心结论

  • 结果展示了一个初步模型,能够根据女性年龄预测获得至少一个整倍体囊胚所需的MII卵母细胞数量,该模型基于迄今用于此目的的最大IVF-PGT-A治疗周期数据库计算,仅纳入对滋养外胚层活检进行下一代测序的治疗周期。
  • 该模型经过适当验证后,可能有助于临床医生和患者在不孕症诊所的决策。

研究设计与样本

  • 回顾性分析西班牙IVIRMA Valencia在2017年1月至2022年3月间进行的体外受精(IVF)治疗周期,均行非整倍体植入前遗传学检测(PGT-A),获IVI Valencia机构审查委员会批准(2204-VLC-040-CR)。
  • 纳入标准为首次IVF-PGT-A治疗周期且至少获得一个MII卵母细胞,不限卵母细胞和精液来源;供卵周期纳入供卵组(≤34岁),自卵周期仅纳入卵母细胞年龄≥35岁的患者组。
  • 仅纳入第5或第6天发育的滋养外胚层活检且使用下一代测序分析的周期;因已知异常核型行PGT-A的周期被排除。
  • 共纳入2660个IVF-PGT-A治疗周期(患者组2462个,供卵组198个)。
  • 使用患者组80%样本(n=2462;训练集)设计调整的多变量二元回归模型,并在剩余20%样本(n=493;验证集)中验证。

主要发现

  • 获得一个整倍体囊胚所需的MII卵母细胞平均数随年龄增加而增加,未获得至少一个整倍体囊胚的治疗周期数也随年龄增加而增加。
  • 基于训练集建立的预测模型在验证集(n=493)中估计至少获得一个整倍体囊胚事件的准确率为72.0%。

临床怎么用

  • 作者认为,该模型经过适当验证后,可能有助于临床医生和患者在不孕症诊所的决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To find a useful tool for estimating the minimum number of metaphase II (MII) oocytes needed to obtain at least one euploid blastocyst according to female age. DESIGN: Retrospective analysis of in vitro fertilization (IVF) treatment cycles with preimplantational genetic testing for aneuploidies (PGT-A) performed over 5 years in IVIRMA Valencia (Spain), January 2017-March 2022. Approval from the Institutional Review Board of IVI Valencia (2204-VLC-040-CR). SETTING: Private infertility clinic in Spain. PATIENTS: Eligible patients were undergoing their first IVF-PGT-A treatment cycle, in which at least one MII oocyte was obtained, regardless of oocyte and semen origin. Oocyte donation cycles were included in the donor group (≤34 years old). Treatment cycles from women with their own oocytes were selected only when the oocytes were aged ≥35 years (patient group). Only trophoectoderm biopsies performed on days 5 or 6 of development and analyzed using next-generation sequencing were included. Preimplantational genetic testing for aneuploidy cycles because of a known abnormal karyotype were excluded. INTERVENTION: Not applicable. MAIN OUTCOME MEASURES: Number of MII oocytes needed to obtain one euploid blastocyst according to female age. RESULTS: A total of 2,660 IVF-PGT-A treatment cycles were performed in the study period in the eligible population (patients group = 2,462; donors group =198). The mean number of MII oocytes needed to obtain one euploid blastocyst increased with age, as did the number of treatment cycles that did not get at least one euploid blastocyst. An adjusted multivariate binary regression model was designed using 80% of the patient group sample (n = 2,462; training set). A calculator for the probability of obtaining at least one euploid blastocyst was created using this model. The validation of this model in the remaining 20% of the patient group sample (n = 493; validation set) showed that it could estimate the event of having at least one euploid blastocyst with an accuracy of 72.0%. CONCLUSIONS: Our results show a preliminary model capable of predicting the number of MII oocytes needed to obtain at least one euploid blastocyst according to female age, calculated with the largest database of IVF-PGT-A treatment cycles ever used for this purpose, including only treatment cycles using next-generation sequencing on trophoectoderm biopsies. Once this model has been properly validated, it could help with decision-making for both clinicians and patients coming to an infertility clinic.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Varela C, Mascarós JM, Labarta E, et al. Minimum number of mature oocytes needed to obtain at least one euploid blastocyst according to female age in in vitro fertilization treatment cycles. Fertil Steril. 2024. PMID: 38848954. doi:10.1016/j.fertnstert.2024.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。